Aspergillus fumigatus osteomyelitis in a patient receiving alemtuzumab for B-cell chronic lymphocytic leukaemia
Something fishy in the immunocompromised
Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia
Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia
Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients
Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals
Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim
Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24 553 patients with Hashimoto’s disease
Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease
Diagnosing pulmonary embolism: a comparison of clinical probability scores
Decreased expression of interleukin-27 in immune thrombocytopenia
Feasibility of DNA diagnosis of haemoglobinopathies on coelocentesis
Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years
Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy
Gene expression profiling: a possible tool in the prediction of outcome in paediatric acute lymphoblastic leukaemia?
Higher risk of primary cancers after polycythaemia vera and vice versa
Burkitt's Lymphoma Symposium
Early Stage Investigator Fellowship